{"id":33780,"date":"2025-05-21T01:58:00","date_gmt":"2025-05-20T17:58:00","guid":{"rendered":"https:\/\/flcube.com\/?p=33780"},"modified":"2025-05-21T01:58:01","modified_gmt":"2025-05-20T17:58:01","slug":"hainan-shuangchengs-generic-eptifibatide-gains-tga-marketing-approval-in-australia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33780","title":{"rendered":"Hainan Shuangcheng&#8217;s Generic Eptifibatide Gains TGA Marketing Approval in Australia"},"content":{"rendered":"\n<p>China&#8217;s Hainan Shuangcheng Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/002693:SHE\">SHE: 002693<\/a>) has received marketing approval from Australia&#8217;s Therapeutic Goods Administration (TGA) for its generic version of eptifibatide. Originally marketed by Schering Corp under the brand name Integrilin, the drug is indicated for patients undergoing elective percutaneous coronary intervention (PCI) and coronary stent implantation, as well as for the treatment of unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI).<\/p>\n\n\n\n<p><strong>Eptifibatide Mechanism and Indications<\/strong><br>Eptifibatide is a synthetic platelet glycoprotein IIb\/IIIa (GPIIb\/IIIa) receptor antagonist. It selectively binds to GPIIb\/IIIa receptors, blocking fibrinogen and von Willebrand factor from binding to these receptors. This action inhibits platelet aggregation and prevents arterial reocclusion. Integrilin was first approved in the US in May 1998 and was initially marketed by Schering. Following the acquisition by Merck Sharp &amp; Dohme (MSD), the drug is now globally available.<\/p>\n\n\n\n<p><strong>Shuangcheng&#8217;s Generic Version<\/strong><br>Shuangcheng Pharmaceutical&#8217;s generic version of eptifibatide gained US FDA approval in 2021. The recent TGA approval in Australia further expands the availability of this important medication, offering more options for patients and healthcare providers.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/ST\u53cc\u6210\uff1a\u6d77\u5357\u53cc\u6210\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u4f9d\u66ff\u5df4\u80bd\u6ce8\u5c04\u6db2\u83b7\u5f97\u6fb3\u5927\u5229\u4e9a\u836f\u7269\u7ba1\u7406\u5c40\uff08TGA\uff09\u4e0a\u5e02\u8bb8\u53ef\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of ST\u53cc\u6210\uff1a\u6d77\u5357\u53cc\u6210\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u4f9d\u66ff\u5df4\u80bd\u6ce8\u5c04\u6db2\u83b7\u5f97\u6fb3\u5927\u5229\u4e9a\u836f\u7269\u7ba1\u7406\u5c40\uff08TGA\uff09\u4e0a\u5e02\u8bb8\u53ef\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-6f80af8b-d0b4-4b60-96ae-efbfa9857101\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/ST\u53cc\u6210\uff1a\u6d77\u5357\u53cc\u6210\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u4f9d\u66ff\u5df4\u80bd\u6ce8\u5c04\u6db2\u83b7\u5f97\u6fb3\u5927\u5229\u4e9a\u836f\u7269\u7ba1\u7406\u5c40\uff08TGA\uff09\u4e0a\u5e02\u8bb8\u53ef\u7684\u516c\u544a.pdf\">ST\u53cc\u6210\uff1a\u6d77\u5357\u53cc\u6210\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u4f9d\u66ff\u5df4\u80bd\u6ce8\u5c04\u6db2\u83b7\u5f97\u6fb3\u5927\u5229\u4e9a\u836f\u7269\u7ba1\u7406\u5c40\uff08TGA\uff09\u4e0a\u5e02\u8bb8\u53ef\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/ST\u53cc\u6210\uff1a\u6d77\u5357\u53cc\u6210\u836f\u4e1a\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5173\u4e8e\u4f9d\u66ff\u5df4\u80bd\u6ce8\u5c04\u6db2\u83b7\u5f97\u6fb3\u5927\u5229\u4e9a\u836f\u7269\u7ba1\u7406\u5c40\uff08TGA\uff09\u4e0a\u5e02\u8bb8\u53ef\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6f80af8b-d0b4-4b60-96ae-efbfa9857101\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has received marketing approval from Australia&#8217;s Therapeutic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33782,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[69,15,3321],"class_list":["post-33780","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cvd","tag-product-approvals","tag-she-002693"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hainan Shuangcheng&#039;s Generic Eptifibatide Gains TGA Marketing Approval in Australia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has received marketing approval from Australia&#039;s Therapeutic Goods Administration (TGA) for its generic version of eptifibatide. Originally marketed by Schering Corp under the brand name Integrilin, the drug is indicated for patients undergoing elective percutaneous coronary intervention (PCI) and coronary stent implantation, as well as for the treatment of unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33780\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hainan Shuangcheng&#039;s Generic Eptifibatide Gains TGA Marketing Approval in Australia\" \/>\n<meta property=\"og:description\" content=\"China&#039;s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has received marketing approval from Australia&#039;s Therapeutic Goods Administration (TGA) for its generic version of eptifibatide. Originally marketed by Schering Corp under the brand name Integrilin, the drug is indicated for patients undergoing elective percutaneous coronary intervention (PCI) and coronary stent implantation, as well as for the treatment of unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33780\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-20T17:58:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-20T17:58:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2006-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33780#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33780\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hainan Shuangcheng&#8217;s Generic Eptifibatide Gains TGA Marketing Approval in Australia\",\"datePublished\":\"2025-05-20T17:58:00+00:00\",\"dateModified\":\"2025-05-20T17:58:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33780\"},\"wordCount\":195,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33780#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2006-1.webp\",\"keywords\":[\"CVD\",\"Product approvals\",\"SHE: 002693\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33780#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33780\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33780\",\"name\":\"Hainan Shuangcheng's Generic Eptifibatide Gains TGA Marketing Approval in Australia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33780#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33780#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2006-1.webp\",\"datePublished\":\"2025-05-20T17:58:00+00:00\",\"dateModified\":\"2025-05-20T17:58:01+00:00\",\"description\":\"China's Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has received marketing approval from Australia's Therapeutic Goods Administration (TGA) for its generic version of eptifibatide. Originally marketed by Schering Corp under the brand name Integrilin, the drug is indicated for patients undergoing elective percutaneous coronary intervention (PCI) and coronary stent implantation, as well as for the treatment of unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33780#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33780\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33780#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2006-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2006-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hainan Shuangcheng's Generic Eptifibatide Gains TGA Marketing Approval in Australia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33780#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hainan Shuangcheng&#8217;s Generic Eptifibatide Gains TGA Marketing Approval in Australia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hainan Shuangcheng's Generic Eptifibatide Gains TGA Marketing Approval in Australia - Insight, China&#039;s Pharmaceutical Industry","description":"China's Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has received marketing approval from Australia's Therapeutic Goods Administration (TGA) for its generic version of eptifibatide. Originally marketed by Schering Corp under the brand name Integrilin, the drug is indicated for patients undergoing elective percutaneous coronary intervention (PCI) and coronary stent implantation, as well as for the treatment of unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33780","og_locale":"en_US","og_type":"article","og_title":"Hainan Shuangcheng's Generic Eptifibatide Gains TGA Marketing Approval in Australia","og_description":"China's Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has received marketing approval from Australia's Therapeutic Goods Administration (TGA) for its generic version of eptifibatide. Originally marketed by Schering Corp under the brand name Integrilin, the drug is indicated for patients undergoing elective percutaneous coronary intervention (PCI) and coronary stent implantation, as well as for the treatment of unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI).","og_url":"https:\/\/flcube.com\/?p=33780","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-20T17:58:00+00:00","article_modified_time":"2025-05-20T17:58:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2006-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33780#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33780"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hainan Shuangcheng&#8217;s Generic Eptifibatide Gains TGA Marketing Approval in Australia","datePublished":"2025-05-20T17:58:00+00:00","dateModified":"2025-05-20T17:58:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33780"},"wordCount":195,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33780#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2006-1.webp","keywords":["CVD","Product approvals","SHE: 002693"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33780#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33780","url":"https:\/\/flcube.com\/?p=33780","name":"Hainan Shuangcheng's Generic Eptifibatide Gains TGA Marketing Approval in Australia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33780#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33780#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2006-1.webp","datePublished":"2025-05-20T17:58:00+00:00","dateModified":"2025-05-20T17:58:01+00:00","description":"China's Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has received marketing approval from Australia's Therapeutic Goods Administration (TGA) for its generic version of eptifibatide. Originally marketed by Schering Corp under the brand name Integrilin, the drug is indicated for patients undergoing elective percutaneous coronary intervention (PCI) and coronary stent implantation, as well as for the treatment of unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33780#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33780"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33780#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2006-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2006-1.webp","width":1080,"height":608,"caption":"Hainan Shuangcheng's Generic Eptifibatide Gains TGA Marketing Approval in Australia"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33780#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hainan Shuangcheng&#8217;s Generic Eptifibatide Gains TGA Marketing Approval in Australia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2006-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33780","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33780"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33780\/revisions"}],"predecessor-version":[{"id":33783,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33780\/revisions\/33783"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33782"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}